This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings?
by Zacks Equity Research
We believe that the growing adoption of Intuitive Surgical's (ISRG) da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the quarter.
Varian Medical Initiates Treatment Using Halcyon System
by Zacks Equity Research
Varian Medical (VAR) has been taking initiatives to gain customers for its broad spectrum of products.
Mazor Robotics Gets CE Mark for Surgical Assurance Platform
by Zacks Equity Research
Earlier this year, Mazor Robotics (MZOR) had announced the receipt of FDA clearance for its Mazor X Align software.
Intuitive Surgical (ISRG) Well Poised on Procedural Business
by Zacks Equity Research
Intuitive Surgical's (ISRG) strong sales growth will continue to be aided by focus on da Vinci system and procedural growth from general surgery, oncology, urology and gynecology.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.
The Zacks Analyst Blog Highlights: Facebook, Air Liquide and Intuitive Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Air Liquide and Intuitive Surgical
Watch Out for the Three Stooges: Global Week Ahead
by John Blank
Q2's biggest earnings week, minutes from the latest FOMC meeting and U.S. GDP Friday may be the Three Musketeers charging markets higher... or, they may become the Three Stooges instead.
Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical posted solid numbers in the quarter under review, courtesy of rising customer adoption of procedures and growth in system placements.
Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More
by Zacks Equity Research
The market remained jittery towards medical space due to uncertainties surrounding the future of the healthcare act.
4 Healthcare Megatrends for Investors
by Kevin Cook
One sector combines the best of science and technology with our dreams for healthier and wealthier lives.
Will Intuitive Surgical (ISRG) Surprise in Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20.
Why Does Intuitive Surgical Score as a Strong Buy Right Now
by Zacks Equity Research
Over the last three months, Intuitive Surgical Inc. (ISRG) was trading consistently ahead of the S&P 500 Index.
The Fed in the Main Circus Tent: Global Week Ahead
by John Blank
On Wednesday, a two-day Federal Open Market Committee (FOMC) meeting produces a 2 pm ET statement. This will be accompanied by fresh forecasts. Consensus expects a 25 basis point rate hike.
Analyst Reports for GM, VMware and Southwest Airlines
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including General Motors (GM), VMware (VMW), and Southwest Airlines (LUV).
Intuitive Surgical da Vinci X Surgical System Okayed by FDA
by Zacks Equity Research
Headquartered in Sunnyvale, CA, Intuitive Surgical Inc. (ISRG) recently announced that the da Vinci X Surgical System, an upgrade to its flagship da Vinci Xi surgical platform, has been cleared by the FDA.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Sunnyvale, CA-based Intuitive Surgical Inc (ISRG) scaled a new 52-week high of $874.54 on May 19, eventually closing a bit lower at $870.33.
Why Is Intuitive Surgical (ISRG) Up 5.4% Since the Last Earnings Report?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Ddown
by Zacks Equity Research
On Apr 21, we issued an updated research report on Sunnyvale-based Intuitive Surgical (ISRG) -- manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories.
After ISRG Q1 Earnings, 3 Medical Instrument Stocks Looking Up
by Zacks Equity Research
While the Medical Instrument industry has been oscillating between hope and despair, let us take a look at three stocks which are expected to put up an impressive show this earnings season like Intuitive Surgical.
Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical Inc.(ISRG) posted adjusted earnings of $4.67 per share in the first quarter of 2017, crushing the Zacks Consensus Estimate of $3.97 on stellar revenue growth.
Should You Make a Bet on the Healthcare Stocks?
by Tracey Ryniec
The healthcare industry is much more than Obamacare and drug prices as many companies are using new technologies to create breakthroughs in medicine.
Will Intuitive Surgical (ISRG) Surprise in Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) is scheduled to report first-quarter 2017 results after the closing bell on Apr 18.
Why Is Intuitive Surgical (ISRG) Up 4.6% Since the Last Earnings Report?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intuitive Surgical Hits 52-Week High on Multiple Positives
by Zacks Equity Research
Shares of leading provider of robotic-assisted surgery, Intuitive Surgical, Inc. (ISRG) rallied to a new 52-week high of $770.28 on Mar 28, closing a tad lower at $764.47.
Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) posted adjusted earnings of $5.30 per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate by four cents.